Favipiravir and COVID-19: A Simplified Summary

Ghasemnejad‐Berenji, Morteza; Pashapour, Sarvin

doi:10.1055/a-1296-7935

Cited by 72 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been supported by many studies that antiviral therapy is effective in the early period ( 20 ). Starting an effective treatment with an agent, such as favipiravir or remdesivir or biologic agents (such as IL-6 blockers) in the first 7 d, might be useful for COVID-19 patients with higher admission CAR values or those demonstrating an increased CAR values during the in-hospital stay ( 21 , 22 , 23 ). This treatment approach might be a crucial and effective in the rapid recovery of symptoms as well as reducing mortality among these patients.…”

Section: Discussionmentioning

confidence: 99%

Predictive Value of CAR for In-Hospital Mortality in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study

Güney¹,

Tastan

Doğantekin³

et al. 2021

Archives of Medical Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Predictive Value of CAR for In-Hospital Mortality in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study

Güney¹,

Tastan

Doğantekin³

et al. 2021

Archives of Medical Research

View full text Add to dashboard Cite

“…The fourth-ranked drug favipiravir is one of the anti-viral agents considered in numerous clinical trials to combat COVID-19. Favipiravir is a purine nucleic acid analog with a broad spectrum of anti-RNA virus activities [56] , [57] , [58] , [59] . In addition, among the top twelve predicted drugs against SARS-CoV-2, many are undergoing clinical trials [60] , [61] .…”

Section: Resultsmentioning

confidence: 99%

A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing

Deepthi

Jereesh

Liu

2021

Applied Soft Computing

View full text Add to dashboard Cite

The alarming pandemic situation of Coronavirus infectious disease COVID-19, caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a critical threat to public health. The unexpected outbreak and unrealistic progression of COVID-19 havegenerated an utmost need torealize promising therapeutic strategiesto fight the pandemic. Drug repurposing-an efficientdrug discovery technique from approved drugs is an emerging tacticto face the immediate global challenge.It offers a time-efficient and cost-effective way to find potential therapeutic agents for the disease. Artificial Intelligence-empowered deep learning models enable the rapid identification of potentially repurposable drug candidates against diseases. This study presents a deep learning ensemble model to prioritize clinically validated anti-viral drugs for their potential efficacy against SARS-CoV-2. The method integrates the similarities of drug chemical structures and virus genome sequences to generate feature vectors. The best combination of features is retrieved by the convolutional neural network in a deep learning manner. The extracted deep features are classified by the extreme gradient boosting classifier to infer potential virus-drug associations. The method could achieve an AUC of 0.8897 with 0.8571 prediction accuracy and 0.8394 sensitivity under the fivefold cross-validation. The experimental results and case studies demonstrate the suggested deep learning ensemble system yields competitive results compared with the state-of-the-art approaches. The top-ranked drugs are released for further wet-lab researches.

show abstract

“…Favipiravir is an antiviral prodrug that has been proven for antiviral efficacy for SARS-CoV-2 during COVID 19 pandemic. 11 It has been used as an antiviral treatment option for COVID 19 in some countries including Turkey. 12,13 She was recommended to have a break for alectinib and brain radiotherapy during COVID 19 since there is no well-established data for continuation of these treatment modalities safely during active COVID 19, especially concurrent application with favipiravir in terms of possible drug interactions.…”

Section: Case Reportmentioning

confidence: 99%

Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?

Akkus

Kaman

Doğan

2021

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Serious Acute Respiratory Syndrome Coronavirus 2 (SARSCoV2) has led to COVID 19 pandemic a year ago and it has not been globally taken under control yet. COVID 19 tends to have poorer prognosis in cancer patients. Additionally, we have no well-established guidelines for management of these patients during pandemic, in terms of treatment of ‘cancer’ and treatment of ‘COVID 19’. Tyrosine kinase inhibitors (TKIs) are given without any break in cancer patients to have better survival outcomes in daily routine. However, there is no well-established data to continue or delay ALK inhibitors in lung cancer patients infected with SARS-CoV2. Concomittant use of ALK inhibitors and COVID 19 antiviral treatment is a dilemma because of the lack of data in this area. Case Report A 47-year old female metastatic ALK positive nonsquamous cell lung cancer patient on alectinib, a second generation ALK inhibitor was diagnosed with symptomatic COVID 19. She was given favipiravir for COVID 19 while continuing alectinib. Management and outcome: The patient continued alectinib during COVID 19 antiviral treatment without any break. She tolerated ‘concomittant’ alectinib & favipiravir. She had partial remission after three months of alectinib without any dose adjustment despite active COVID 19 medication. Discussion To best of our knowledge, this is the first case who continued alectinib without dose adjustment during antiviral COVID-19 medication without clinically worsening. There is limited data about ‘concomittant’ use of TKIs and antiviral COVID 19 medication in the literature. There are some case reports, but they generally tended to delay or suspend TKIs during COVID 19 antiviral medication. Our case differs from them in terms of continuation of alectinib without any break or additional side effects during favipiravir for symptomatic COVID 19. We consider that our case might contribute to the literature in terms of management of cancer patients on targeted therapy during COVID 19 antiviral treatment. However, clinical trials are needed in this area.

show abstract

Favipiravir and COVID-19: A Simplified Summary

Cited by 72 publications

References 26 publications

Predictive Value of CAR for In-Hospital Mortality in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study

Predictive Value of CAR for In-Hospital Mortality in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study

A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing

Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?

Contact Info

Product

Resources

About